Dr. Matthew Schlumbrecht, MD, MPH
Claim this profileUniversity of Miami Miller School of Medicine-Sylvester Cancer Center
Area of expertise
Ovarian Cancer
Matthew Schlumbrecht, MD, MPH has run 5 trials for Ovarian Cancer. Some of their research focus areas include:
Endometrial Cancer
Matthew Schlumbrecht, MD, MPH has run 1 trial for Endometrial Cancer. Some of their research focus areas include:
Affiliated Hospitals
University Of Miami Miller School Of Medicine-Sylvester Cancer Center
UM Sylvester Comprehensive Cancer Center At Coral Gables
Clinical Trials Matthew Schlumbrecht, MD, MPH is currently running
Lenvatinib + Pembrolizumab + Radiation
for Endometrial Cancer
This trial tests if combining an immune-boosting drug, a cancer-fighting pill, and shorter radiation treatments can help treat pelvic area cancer by boosting the immune system, stopping cancer growth, and killing cancer cells.
Recruiting
1 award
Phase 1
Neratinib or Neratinib + Palbociclib
for Cancer
This phase II ComboMATCH treatment trial compares the effect of neratinib to the combination of neratinib and palbociclib in treating patients with HER2 positive solid tumors. Neratinib and palbociclib are in a class of medications called kinase inhibitors. They work by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of tumor cells. Giving neratinib and palbociclib in combination may shrink or stabilize cancers that over-express a specific biomarker called HER2.
Recruiting
1 award
Phase 2
More about Matthew Schlumbrecht, MD, MPH
Clinical Trial Related
2 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 5 Active Clinical Trials
Treatments Matthew Schlumbrecht, MD, MPH has experience with
- Niraparib
- Hypofractionated External Beam Radiation Therapy
- Lenvatinib
- Pembrolizumab
- Anetumab Ravtansine
- Bevacizumab
Breakdown of trials Matthew Schlumbrecht, MD, MPH has run
Ovarian Cancer
Endometrial Cancer
Ovarian Adenocarcinoma
Peritoneal Carcinoma
Peritoneal Serous Adenocarcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Matthew Schlumbrecht, MD, MPH specialize in?
Matthew Schlumbrecht, MD, MPH focuses on Ovarian Cancer and Endometrial Cancer. In particular, much of their work with Ovarian Cancer has involved BRCA1 positive patients, or patients who are Stage IV.
Is Matthew Schlumbrecht, MD, MPH currently recruiting for clinical trials?
Yes, Matthew Schlumbrecht, MD, MPH is currently recruiting for 5 clinical trials in Miami Florida. If you're interested in participating, you should apply.
Are there any treatments that Matthew Schlumbrecht, MD, MPH has studied deeply?
Yes, Matthew Schlumbrecht, MD, MPH has studied treatments such as Niraparib, Hypofractionated External Beam Radiation Therapy, Lenvatinib.
What is the best way to schedule an appointment with Matthew Schlumbrecht, MD, MPH?
Apply for one of the trials that Matthew Schlumbrecht, MD, MPH is conducting.
What is the office address of Matthew Schlumbrecht, MD, MPH?
The office of Matthew Schlumbrecht, MD, MPH is located at: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida 33136 United States. This is the address for their practice at the University of Miami Miller School of Medicine-Sylvester Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.